CINCOR PHARMA, INC.
200 Clarendon Street, 6th Floor
Boston, Massachusetts 02116
|January 4, 2022||VIA EDGAR|
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Michael Fay
CinCor Pharma, Inc.
Registration Statement on Form S-1
File No. 333-261738
|Requested Date:||January 6, 2022|
|Requested Time:||4:00 P.M. Eastern Time|
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 (the Registration Statement) to become effective on January 6, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Patrick Kavanaugh, counsel to the Registrant, at (212) 479 6767.
Very truly yours,
|CinCor Pharma, Inc.|
Marc de Garidel
Chief Executive Officer
Ryan Sansom, Cooley LLP
Divakar Gupta, Cooley LLP
Courtney Thorne, Cooley LLP